Long-term follow-up of patients with hypereosinophilic syndrome treated with alemtuzumab, an anti-CD52 antibody

Paolo Strati, Jorge Cortes, Stefan Faderl, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term follow-up of patients with hypereosinophilic syndrome treated with alemtuzumab, an anti-CD52 antibody'. Together they form a unique fingerprint.

Medicine & Life Sciences